Apolipoproteins C–III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde
Open accessAbstract
Apolipoprotein (apo) C-III and apoE are components of two major classes of plasma lipoproteins, i.e., apoB- and non-apoB-containing lipoproteins. To analyze the relationship between the distribution of apoC-III and apoE among lipoproteins and coronary heart disease, we compared the distribution of these two apolipoproteins in survivors of myocardial infarction (MI) and control subjects, within and between populations at contrasting risk for MI. ApoC-III and apoE concentrations were determined in plasma devoid of apoB-containing lipoproteins by immunoprecipitation using a specific anti-apoB antiserum. These assays referred to apoC-III-Lp non-B and apoE-Lp non-B, respectively. By examining the difference with total plasma apoC-III and apoE levels, we calculated apoC-III and apoE in apoB-containing lipoproteins (apoCIII-LpB and apoE-LpB, respectively). These determinations were performed in control subjects and in survivors of MI, all males aged 25 to 64 years. They were recruited in Northern Ireland and France, countries characterized by a large difference in the incidence of coronary heart disease. In univariate analysis, apoCIII-LpB appeared significantly higher and the apoC-III ratio (apoC-III-Lp non-B/apoC-III-LpB) significantly lower in MI survivors than in control subjects in both countries. ApoE-LpB was higher in MI survivors than in control subjects in Northern Ireland but not in France. The two French and Irish control populations differed for apoC-ILL-Lp non-B, apoC-I…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In 489 control subjects without CHD not taking hypolipidemic drugs, apoC-III-Lp nonB was significantly correlated with HDL apoA-I concentration.
“This is supported by the data of Luc et al. (46), showing that in 489 control subjects without CHD not taking hypolipidemic drugs, apoC-III-Lp nonB (measured by electroimmunassay after immunoprecipitation of apoB-containing lipoproteins) was significantly correlated with HDL cholesterol and apoA-I concentrations.”
From Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans (2003) · cites this paper as [46]
In 489 control subjects without CHD not taking hypolipidemic drugs, apoC-III-Lp nonB was significantly correlated with HDL cholesterol concentration.
“This is supported by the data of Luc et al. (46), showing that in 489 control subjects without CHD not taking hypolipidemic drugs, apoC-III-Lp nonB (measured by electroimmunassay after immunoprecipitation of apoB-containing lipoproteins) was significantly correlated with HDL cholesterol and apoA-I concentrations.”
From Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans (2003) · cites this paper as [46]
ApoE-Lp nonB was only weakly correlated with HDL cholesterol and apoA-I.
“ApoE-Lp nonB on the other hand was only weakly correlated with HDL cholesterol and apoA-I.”
From Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans (2003) · cites this paper as [46]
The citation lists haven’t been fetched yet
References 53 · Cited by 114
- Authors
- Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P.
- Affiliations
- Institut Pasteur de Lille (FR)
- ORCID
- Bard, J M
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 1996-03
- Volume
- 37
- Issue
- 3
- Pages
- 508-517
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W1921210832
- Cited by
- 114
- References
- 53
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 2 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 5 · 2014: 1 · 2013: 9 · 2012: 3
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, apolipoprotein E, apoB-containing lipoproteins, myocardial infarction survivors, coronary heart disease risk, HDL cholesterol, triglycerides, apolipoprotein A-I, apolipoprotein B
- MeSH terms
- Adult, Apolipoproteins B, Apolipoproteins C, Apolipoproteins E, Disease Susceptibility, France, Humans, Immunoassay, Ireland, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Regression Analysis, Risk Factors, World Health Organization, Multivariate Analysis, Case-Control Studies, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
